Adaptive daily replanning of radiotherapy for head and neck cancer.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The intervention uses daily online adaptive radiotherapy with same-day replanning and optimization to account for anatomical changes during a curative course of radiotherapy for pharyngeal or laryngeal squamous cell carcinoma. Imaging is acquired before each fraction and the treatment plan is modified to spare nearby organs at risk when anatomy has shifted. The main goals are to test feasibility of the workflow and to see if daily adaptation lowers radiation dose to healthy tissues and reduces acute and late toxicity. Eligible patients are treated at Rigshospitalet in Copenhagen and include adults with histologically proven pharynx or larynx SCC (stage I–IV excluding T1–T2N0 glottic), ECOG 0–2, without prior head and neck radiotherapy or distant metastases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically proven squamous cell carcinoma of the pharynx or larynx planned for primary radiotherapy with curative intent No current or earlier malignancies, which may influence treatment, evaluation or outcome of the head-neck cancer Informed consent as required by law The patient cannot participate in conflicting protocols Stage I-IV (excluding T1-T2N0 carcinoma of the glottic larynx) ECOG/WHO performance status 0-2

Exclusion Criteria:

Patient with cancers of the glottic larynx (stage I/II), skull base, sino-nasal area and unknown primary tumor.

Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic Distant metastasis Previous radiotherapy of the head and neck Previous surgery for the primary cancer with curative intent

\-

Where it's running

• Rigshospitalet
  Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Jeppe Friborg, MD, PhD
• Email: jeppe.friborg@regionh.dk
• Phone: +45 35458189

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Postbiotix-HLA™ with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.

  This trial will test whether taking the postbiotic supplement Postbiotix-HLA™ with first-line pembrolizumab reduces immune-related side effects and alters microbiota in people with recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting Phase 2 Gruppo Oncologico del Nord-Ovest · Rozzano, Milano · NCT07485296

• Early PET/CT response after first‑line pembrolizumab in recurrent or metastatic head and neck cancer

  This project will see if an 18F‑FDG PET/CT scan after two doses of pembrolizumab can tell who is responding among patients with recurrent or metastatic PD‑L1 CPS ≥1 head and neck cancer.

  Recruiting University of Rome Tor Vergata · Rome, Italy · NCT07448727

• Postoperative radiotherapy with nimotuzumab followed by bemcentinib for high-risk head and neck cancer patients who can't take cisplatin

  This study will see if adding nimotuzumab during postoperative radiotherapy followed by bemcentinib can help prevent recurrence in high-risk head and neck cancer patients who are unable to receive cisplatin.

  Recruiting Phase 3 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai · NCT07445048

• 4D dynamic LAFOV FDG-PET to tell leftover cancer from post-radiation inflammation in head and neck squamous cell carcinoma

  This study will test whether a 4D dynamic long‑axial‑field‑of‑view FDG‑PET scan can tell remaining head and neck squamous cell cancer from normal post‑radiation inflammation in adults about three months after finishing curative radiotherapy.

  Recruiting University Hospital, Brest · Brest and 2 other locations · NCT07417605

• Radiotherapy with nimotuzumab versus radiotherapy alone for platinum-ineligible advanced head and neck squamous cell carcinoma

  This trial tests whether adding nimotuzumab to radiotherapy helps people with advanced head and neck squamous cell carcinoma who cannot receive platinum chemotherapy.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Shandong, Province · NCT07333274

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.